Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?. Issue 10 (19th March 2019)

• Record Type: Journal Article
• Authors: Nelson, David B; Mitchell, Kyle G; Weston, Brian R; Betancourt, Sonia; Maru, Dipen; Rice, David C; Mehran, Reza J; Sepesi, Boris; Antonoff, Mara B; Walsh, Garrett L; Swisher, Stephen G; Roth, Jack A; Vaporciyan, Ara A; Blum, Mariela; Hofstetter, Wayne L
• Is Part Of: Diseases of the esophagus. Volume 32:Issue 10(2019)
• Page Start: 1
• Page End: 6
• Publication Date: 2019-03-19
• Subjects: cancer staging -- endoscopic mucosal resection -- endoscopic ultrasound -- esophageal adenocarcinoma; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doz016
• Languages: English
• ISSNs: 1120-8694

Abstract

SUMMARY: Endoscopic mucosal resection (EMR) can be an effective therapy for superficial esophageal cancer. Many patients with cT2 invasion by endoscopic ultrasound (EUS) receive surgery but are subsequently found to have superficial disease. The purpose of this study was to investigate the safety profile and the added value of attempting EMR for EUS-staged cT2N0 esophageal cancer. A retrospective review was performed at a single institution from 2008 to 2017. Patients who were staged cT2N0 by EUS were identified from a prospectively maintained surgical database. Among 75 patients identified for analysis, 30 underwent an attempt at EMR. No perforations or other immediate complications occurred. EMR was more likely to be attempted among older patients ( P = 0.001) with smaller tumor size ( P < 0.001) and diminished SUVmax ( P = 0.001). At the time of treatment, EMR was successful in clearing all known disease among 17/30 patients, with 12 representing pT1a or less and 5 representing pT1b with negative margins. Among the 17 patients for whom EMR was able to clear all known disease, there were no recurrences or cancer-related deaths. Although all the patients were staged as cT2N0 by EUS, many patients were identified by EMR to have superficial disease. There were no perforations or other adverse events related to EMR. Furthermore, EMR cleared all known disease among 17 patients with no known recurrences or cancer-related deaths. The results indicate that EMR for cT2N0 esophageal cancer is a safe diagnostic option that is therapeutic for some.